An anti-parasitic drug could be the COVID-19 antiviral we need Researchers from Australia have confirmed that an FDA-approved anti-parasitic agent called Ivermectin can inhibit SARS-Cov2 replication in the cell and have proposed it as a candidate for further clinical trials.
Researchers from Australia have confirmed that an FDA-approved anti-parasitic agent called Ivermectin can inhibit SARS-Cov2 replication in…